《大行報告》瑞銀首予騰盛博藥-B(02137.HK)「買入」評級 目標價47.3元
瑞銀發表研究報告,首次給予騰盛博藥(02137.HK)「買入」評級,指出公司專注於研發乙型肝炎病毒、HIV、細菌感染、新冠病毒等重大傳染病的創新療法,目前產品線有逾10個項目。
該行估計,騰盛博藥的中和抗體將於明年首次商業化,核心HBV項目料於2024至2025年商業化,預測峰值銷售額將達到159億元人民幣,其中兩款產品BRII-179及BRII-835風險調整後峰值銷售額料達到114億元人民幣。
瑞銀表示,雖然多個項目仍處於初期階段,但騰盛博藥有不少項目具有發展為「同類第一」(First-in-class)的潛力,給予目標價47.3元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.